Reviva Pharmaceuticals Holdings, Inc. to Post FY2024 Earnings of ($0.91) Per Share, Zacks Small Cap Forecasts (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Investment analysts at Zacks Small Cap lifted their FY2024 earnings estimates for shares of Reviva Pharmaceuticals in a research report issued on Monday, August 26th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.91) for the year, up from their previous forecast of ($0.92). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.98) per share.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02.

Several other research firms also recently issued reports on RVPH. Benchmark restated a “speculative buy” rating and set a $17.00 price objective on shares of Reviva Pharmaceuticals in a report on Monday, August 26th. Maxim Group restated a “hold” rating on shares of Reviva Pharmaceuticals in a research note on Friday, August 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Reviva Pharmaceuticals in a report on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Reviva Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.

Reviva Pharmaceuticals Trading Up 5.7 %

RVPH opened at $1.12 on Thursday. Reviva Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $6.80. The business has a 50 day moving average of $1.05 and a 200-day moving average of $2.21. The stock has a market capitalization of $33.40 million, a price-to-earnings ratio of -0.70 and a beta of -0.09.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Armistice Capital LLC grew its stake in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 194.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,764,000 shares of the company’s stock after purchasing an additional 1,164,000 shares during the period. Armistice Capital LLC owned approximately 6.32% of Reviva Pharmaceuticals worth $9,085,000 as of its most recent filing with the Securities and Exchange Commission. 63.18% of the stock is owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.